Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 3/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676164 | 0.99 | ATAD2 (0.63) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2676018 | 0.93 | ATAD2 (0.53) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2676270 | 0.92 | ATAD2 (0.59) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2676461 | 0.92 | ATAD2 (0.55) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2676091 | 0.91 | ATAD2 (0.60) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2675626 | 0.88 | ATAD2 (0.60) | ATAD2NOS3NOS1NOS2DRD2 | |
| SCHEMBL2676156 | 0.82 | ATAD2 (0.56) | ATAD2DRD2DRD4DRD3CHRM1 | |
| SCHEMBL2791541 | 0.81 | GRIN1 (0.56) | ATAD2NOS3NOS1DRD2DRD4 | |
| SCHEMBL28901304 | 0.81 | CHRM1 (0.53) | NOS3NOS1NOS2DRD2DRD4 | |
| SCHEMBL29923967 | 0.81 | CHRM1 (0.53) | NOS3NOS1NOS2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | ATAD2 1833/4885NOS3 3/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.